Effectiveness of antiresorptive drugs in patients with systemic sclerosis and osteoporosis - a retrospective monocentric study

Justus-Liebig-Universität, Campus Kerckhoff0 个研究点目标入组 300 人开始时间: 2024年1月15日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Positive classification of the ACR/EULAR classification criteria for systemic sclerosis from 2013
•Bone density reduction (osteoporosis/osteopenia) with indication for osteospecific therapy according to DVO guideline 2017
•Treatment with bisphosphonates, raloxifene or denosumab
•Presence of at least 2 bone density measurements (DXA) (before and during or after osteospecific therapy; interval of 2 years between measurements)

•Interrupted therapy with antiresorptive drugs
•Undergoing osteoanabolic therapy
•Other secondary forms of osteoporosis, in particular:
•- Intake of > 5 mg prednisolone equivalent/day
•- Diabetes mellitus type I
•- Intake of growth hormones, estrogens, aromatase inhibitors, other tumor therapies
•- Heart failure with an EF < 35 %
•- Hyperthyroidism (with the exception of hyperthyroidism factitia)
•- Chronic renal insufficiency KDIGO stage 3b or higher
•- Hyperparathyroidism

发起方

Justus-Liebig-Universität, Campus Kerckhoff